Skip to content
Screener

Debt Repayments at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
$0-100%
Sotera Health logo
Sotera HealthSHC
$3.56M-5.7%
Fortrea Holdings Inc. logo
Fortrea Holdings Inc.FTRE
$0
Revvity logo
RevvityRVTY
$0+100%
IQVIA logo
IQVIAIQV
$687M+1,461%
Quest Diagnostics logo
Quest DiagnosticsDGX
$500M+24.7%

Other financials

Income statement

See full
Revenue$1.0B-2.7%
Gross profit$349.0M-3.5%
Operating income$119.9M+19.7%
Net income-$1.5M-103%
EPS (diluted)-$0.03-103%

Balance sheet

See full
Cash & equivalents$240.6M+30.2%
Total debt$3.0B+8.1%
Total equity$2.8B-15.3%
Total assets$7.5B-0.4%

Cash flow

See full
Operating cash flow$179.7M-12.2%
CapEx$31.1M-11.9%
Free cash flow$148.6M-12.2%

Valuation

See full
Market cap$11.28B+70.1%
Enterprise value$14.08B+53.4%
P/S2.8×+1.2×

Profitability

See full
Gross margin84.7%
Operating margin13%-2.4pp
Net margin-6%
FCF margin9.3%-5.1pp

Returns & leverage

See full
Return on equity-7.7%
Debt / equity1.1×+0.2×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities.

The source filing: Charles River Laboratories’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 9:21 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001100682-26-000118
Line itemSix Months Ended / June 27, 2026Six Months Ended / June 28, 2025
Net cash used in investing activities(379,748)(82,818)
Cash flows relating to financing activities
Proceeds from long-term debt and revolving credit facility1,265,258963,363
Payments on long-term debt, revolving credit facility, and finance lease obligations(745,927)(887,706)
Proceeds from exercises of stock options1,6201
Purchase of treasury stock(323,881)(360,484)
Payments of contingent consideration(11,400)(21,822)
Purchase of remaining equity interests of other redeemable noncontrolling interest(19,140)

Item 1. Financial Statements

FAQ

What is Charles River Laboratories's debt repayments?
Charles River Laboratories (CRL) reported debt repayments of $390.25M in Q2 2026.
How has Charles River Laboratories's debt repayments changed year-over-year?
Charles River Laboratories's debt repayments decreased by 47.1% year-over-year, from $738.31M to $390.25M.
What is the long-term trend for Charles River Laboratories's debt repayments?
Over 4 years (2021 to 2025), Charles River Laboratories's debt repayments has grown at a -31.8% compound annual growth rate (CAGR), from $6.24B to $1.35B.
What does debt repayments mean?
Cash used to repay or retire outstanding debt obligations, including scheduled maturities and early redemptions.

Ask your AI about Charles River Laboratories's debt repayments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude